Diabetes Insipidus Clinical Trial
OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II
(AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by
directing the production of an abnormal preprohormone.
II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys
magnocellular neurons because it cannot be folded and processed efficiently.
PROTOCOL OUTLINE: This project involves 2 clinical studies. Members of known kindreds
participate in Study I; members of kindreds who have not been surveyed, genotyped, or
phenotyped participate in Study II.
In Study I, participants undergo clinical, hormonal, radiologic, and biochemical studies.
Assessment on unrestricted fluid intake includes body weight, urine volume, osmolality,
creatinine, sodium, potassium, urea, glucose, arginine-vasopressin (AVP), oxytocin, and
aquaporin-II.
Participants with diabetes insipidus (DI) undergo a standard fluid deprivation test; those
without DI undergo standard water load and hypertonic saline testing.
Previously untreated DI patients may be given intranasal or subcutaneous desmopressin or
oral chlorpropamide (adults only) for 2 or 3 days.
Magnetic resonance imaging of the pituitary-hypothalamic area is performed on all patients
with and without gadolinium.
Infants and children are studied annually for the first 5 years or until they develop DI.
Affected adults are studied every 2-5 years. Unaffected adults are re-tested only if they
subsequently report de novo symptoms suggestive of DI.
In Study II, participants undergo similar genotype and phenotype testing. Kindreds
demonstrating the familial neurohypophyseal diabetes insipidus phenotype and genotype are
added to Study I. Kindreds found to have a different type of DI are directed into a
companion protocol.
;
Primary Purpose: Screening
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03572166 -
Use of Copeptin Measurement After Arginine Infusion for the Differential Diagnosis of Diabetes Insipidus - the CARGOx Study
|
N/A | |
| Completed |
NCT04550520 -
Copeptin After a Subcutaneous Stimulation With Glucagon in Adults
|
N/A | |
| Terminated |
NCT02460354 -
Metformin and Congenital Nephrogenic Diabetes Insipidus
|
Phase 1 | |
| Completed |
NCT02523001 -
Effect of Statin Treatment on Urinary AQP2 (uAQP2/01)
|
N/A | |
| Active, not recruiting |
NCT04351945 -
Endocrine Changes and Their Correction in Heart and Lung Transplant Recipients and Donors
|
||
| Completed |
NCT00757276 -
Copeptin in the Diagnosis and Differential Diagnosis of Diabetes Insipidus. The CoSIP-Study
|
N/A | |
| Completed |
NCT01940614 -
Use of Copeptin in Diabetes Insipidus
|
||
| Recruiting |
NCT02841553 -
Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study
|
||
| Completed |
NCT04648137 -
Circulating Oxytocin Changes in Response to the Oxytocin System Stimulator MDMA in Patients With Diabetes Insipidus and Healthy Controls
|
N/A | |
| Active, not recruiting |
NCT00004364 -
Study of Novel Types of Familial Diabetes Insipidus
|
N/A | |
| Completed |
NCT02132676 -
Shared Health Appointments and Reciprocal Enhanced Support
|
||
| Completed |
NCT02455414 -
Tracking Neurodegeneration in Early Wolfram Syndrome
|